Camille L. Bedrosian M.D.
Net Worth
Last updated:
What is Camille L. Bedrosian M.D. net worth?
The estimated net worth of Dr. Camille L. Bedrosian M.D. is at least $7,065,694 as of 1 Mar 2023. He owns shares worth $1,396,928 as insider, has earned $1,446,666 from insider trading and has received compensation worth at least $4,222,100 in Ultragenyx Pharmaceutical Inc..
What is the salary of Camille L. Bedrosian M.D.?
Dr. Camille L. Bedrosian M.D. salary is $844,420 per year as Chief Medical Officer & Executive Vice President in Ultragenyx Pharmaceutical Inc..
How old is Camille L. Bedrosian M.D.?
Dr. Camille L. Bedrosian M.D. is 72 years old, born in 1953.
What stocks does Camille L. Bedrosian M.D. currently own?
As insider, Dr. Camille L. Bedrosian M.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | Chief Medical Officer & Executive Vice President | 46,720 | $29.9 | $1,396,928 |
What does Ultragenyx Pharmaceutical Inc. do?
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Camille L. Bedrosian M.D. insider trading
Ultragenyx Pharmaceutical Inc.
Dr. Camille L. Bedrosian M.D. has made 12 insider trades between 2020-2023, according to the Form 4 filled with the SEC. Most recently he sold 3,881 units of RARE stock worth $175,615 on 1 Mar 2023.
The largest trade he's ever made was exercising 25,000 units of RARE stock on 15 Jan 2021. As of 1 Mar 2023 he still owns at least 46,720 units of RARE stock.
Ultragenyx Pharmaceutical key executives
Ultragenyx Pharmaceutical Inc. executives and other stock owners filed with the SEC:
- Dr. Camille L. Bedrosian M.D. (72) Chief Medical Officer & Executive Vice President
- Dr. Emil D. Kakkis M.D., Ph.D. (65) Pres, Chief Executive Officer & Director
- Mr. Erik Harris (55) Executive Vice President & Chief Commercial Officer
- Mr. John Richard Pinion II (59) Chief Quality Operations Officer & Executive Vice President of Translational Sciences
- Ms. Mardi C. Dier (61) Executive Vice President & Chief Financial Officer